title: Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis.
abstract: OBJECTIVE
  To investigate whether use of adalimumab decreases the frequency of attacks of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).
  
  
  METHODS
  Consecutive patients with AS, visiting an outpatient clinic and treated for at least 12 weeks with adalimumab, were enrolled. The number of attacks of AU in the year before start and during treatment were assessed by patient history and ophthalmological controls.
  
  
  RESULTS
  In the 77 patients a total of 52 AU attacks occurred in the year before baseline (68 attacks per 100 patient-yrs), whereas during adalimumab treatment 19 attacks were seen (14 per 100 patient-yrs; reduction rate 80%). Twenty-six patients with AU in the year before start of adalimumab treatment had recurrent attacks, with a median number of 2.0 AU attacks per year [interquartile range (IQR) 1.00-3.00], whereas during treatment this decreased to 10 patients with a median number of 0.56 attacks per year (IQR 0.30-0.75). Hence, the number of attacks per year decreased by 72% (p = 0.000).
  
  
  CONCLUSIONS
  In patients with AS, a significant reduction in the number of AU attacks, as well as in the number of attacks per patient, was observed during adalimumab treatment.
authors.affiliation: From the Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; and Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.J.C. van Denderen, MD; I.M. Visman, Department of Rheumatology, Jan van Breemen Research Institute Reade; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; M.S.A. Suttorp-Schulten, MD, PhD, Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, VU University Medical Center.
authors.forename: J Christiaan
authors.initials: JC
authors.lastname: van Denderen
authors.affiliation: From the Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; and Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.J.C. van Denderen, MD; I.M. Visman, Department of Rheumatology, Jan van Breemen Research Institute Reade; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; M.S.A. Suttorp-Schulten, MD, PhD, Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, VU University Medical Center.
authors.forename: Ingrid M
authors.initials: IM
authors.lastname: Visman
authors.affiliation: From the Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; and Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.J.C. van Denderen, MD; I.M. Visman, Department of Rheumatology, Jan van Breemen Research Institute Reade; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; M.S.A. Suttorp-Schulten, MD, PhD, Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, VU University Medical Center.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Nurmohamed
authors.affiliation: From the Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; and Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.J.C. van Denderen, MD; I.M. Visman, Department of Rheumatology, Jan van Breemen Research Institute Reade; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; M.S.A. Suttorp-Schulten, MD, PhD, Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, VU University Medical Center.
authors.forename: Maria S A
authors.initials: MS
authors.lastname: Suttorp-Schulten
authors.affiliation: From the Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; and Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.J.C. van Denderen, MD; I.M. Visman, Department of Rheumatology, Jan van Breemen Research Institute Reade; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Jan van Breemen Research Institute Reade, and Department of Rheumatology, VU University Medical Center; M.S.A. Suttorp-Schulten, MD, PhD, Department of Ophthalmology, Onze Lieve Vrouwe Gasthuis; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, VU University Medical Center. ie.vanderhorst@vumc.nl.
authors.forename: Irene E
authors.initials: IE
authors.lastname: van der Horst-Bruinsma
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013167:Spondylitis, Ankylosing / Q000150:complications*; D016896:Treatment Outcome; D014606:Uveitis, Anterior / Q000150:complications / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab
keywords: ADALIMUMAB; ANKYLOSING SPONDYLITIS; UVEITIS